<table sstyle="width:80%" align="center" border=1>
<tr>
<th>mv</th>
<th>dw</th>
<th>HMMCrowd</th>
</tr>
<tr>
<td width=33%>
[136, 138] Survival analysis<br>[209, 212] overall survival rates<br>[235, 240] progression-free survival rates<br>[265, 266] toxicity<br>[313, 314] no<br>[317, 318] deaths<br></td>
<td width=33%>
[17, 24] overall and progression-free survival.<br>[136, 138] Survival analysis<br>[208, 212] 5-year overall survival rates<br>[234, 240] 5-year progression-free survival rates<br>[263, 266] significantly more toxicity<br>[274, 278] leukopenia and emesis,<br>[313, 314] no<br>[317, 318] deaths<br></td>
<td width=33%>
[10, 14] advanced nasopharyngeal carcinoma:<br>[17, 25] overall and progression-free survival.

<br>[136, 156] Survival analysis was estimated by the Kaplan-Meier method and compared by the log-rank test.
<br>[157, 160] Baseline patient characteristics<br>[194, 196] tumor relapse<br>[208, 212] 5-year overall survival rates<br>[234, 240] 5-year progression-free survival rates<br>[263, 266] significantly more toxicity<br>[274, 279] leukopenia and emesis, compliance<br>[313, 318] no treatment-related deaths<br></td>
</tr>
